Related Experiment Videos
New issues in oral anticoagulants.
1University of Rochester Medical Center, Rochester, NY 14642-0001, USA. charles_francis@urmc.rochester.edu
Hematology. American Society of Hematology. Education Program
|December 17, 2008
Summary
Pharmacogenomic algorithms improve warfarin dosing accuracy compared to clinical factors alone. New oral anticoagulants, including direct thrombin and Factor Xa inhibitors, show promise as warfarin alternatives for preventing venous thromboembolism.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Anticoagulation Therapy
Background:
- Warfarin dosing is influenced by genetic variations in CYP2C9 and VKORC1 enzymes.
- CYP2C9 polymorphisms affect warfarin metabolism, with *1 having higher activity than *2 or *3 variants.
- VKORC1 polymorphisms result in high or low haplotypes, impacting warfarin dose requirements.
Purpose of the Study:
- To evaluate the efficacy of pharmacogenomic algorithms in warfarin dosing.
- To review the development and clinical trial outcomes of novel oral anticoagulants as warfarin alternatives.
Main Methods:
- Analysis of CYP2C9 and VKORC1 polymorphisms for warfarin dose adjustment.
- Review of Phase III clinical trial data for dabigatran, rivaroxaban, and apixaban in VTE prevention and stroke risk reduction.
Main Results:
- Pharmacogenomic dosing algorithms demonstrate superior performance over clinical data alone.
- Dabigatran showed non-inferiority to enoxaparin for VTE prevention post-hip/knee replacement.
- Rivaroxaban was superior to enoxaparin in VTE prevention after hip/knee replacement without increased bleeding.
Conclusions:
- Pharmacogenomic information enhances warfarin dosing precision.
- Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) represent promising alternatives to warfarin for anticoagulation.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...